Publicaciones en colaboración con investigadores/as de Rush University Medical Center (20)

2023

  1. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts

    International Journal of Molecular Sciences, Vol. 24, Núm. 20

2022

  1. Melphalan flufenamide for relapsed/refractory multiple myeloma

    Drugs of today (Barcelona, Spain : 1998), Vol. 58, Núm. 8, pp. 407-423

  2. Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL

    Leukemia and Lymphoma, Vol. 63, Núm. 9, pp. 2063-2073

  3. Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study

    British Journal of Haematology, Vol. 196, Núm. 3, pp. 639-648

  4. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1999-2012.e6

  5. Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2025-2038.e1

2021

  1. Impact of Bacillus Calmette-Gue´rin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection

    BJS Open

  2. Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: The COVIDSurg mortality score

    British Journal of Surgery, Vol. 19, Núm. 4

  3. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 7, pp. 757-767

  4. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal

    HemaSphere, Vol. 5, Núm. 11, pp. E646

2018

  1. Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data

    The Lancet Neurology, Vol. 17, Núm. 10, pp. 895-904

2017

  1. Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: A retrospective multinational study

    International Journal of Molecular Sciences, Vol. 18, Núm. 4

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

2015

  1. Designing a broad-spectrum integrative approach for cancer prevention and treatment

    Seminars in Cancer Biology, Vol. 35, pp. S276-S304

2014

  1. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus

    Blood, Vol. 124, Núm. 9, pp. 1404-1411

2012

  1. Guidelines for the use and interpretation of assays for monitoring autophagy

    Autophagy, Vol. 8, Núm. 4, pp. 445-544

2008

  1. Primary epithelioid angiosarcoma of the thyroid: An infrequent malignant thyroid tumor

    Endocrinologia y Nutricion, Vol. 55, Núm. 4, pp. 181-183

2007

  1. A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma

    Leukemia and Lymphoma, Vol. 48, Núm. 1, pp. 39-45

2004

  1. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma

    Biology of Blood and Marrow Transplantation, Vol. 10, Núm. 10, pp. 698-708